CD8A and melanoma: Studies in melanoma models have demonstrated that the frequency of a progenitor exhausted CD8+ T cell population, which persists long‐term, responds to anti‐PD‐1 therapy, and ultimately differentiates into terminally exhausted cells within tumor‐infiltrating T cells, anticipates favorable clinical results for melanoma treated with ICB.[11, 82] This analysis provided insight into the patterns of TAM and CD8+ T cell infiltration that may underlie treatment resistance.